F1000 highlights

OBJECTIVE The purpose of this study was to determine the implication of idiopathic pulmonary fibrosis on the surgical treatment for primary lung cancer. METHODS Between January 1994 and June 2006, 870 patients with primary lung cancer were surgically treated. Fifty-six (6.4%) of 870 patients had complications with idiopathic pulmonary fibrosis, and their data were retrospectively reviewed. There were 50 men and 6 women with an average age of 68 years. The incidence of squamous cell carcinoma was 28 (50.0%). Surgical procedures consisted of 7 wedge resections of the lung, 5 segmentectomies, 43 lobectomies, and 1 bilobectomy. RESULTS Surgery-related hospital mortality was higher in patients with idiopathic pulmonary fibrosis than in patients without (7.1% vs 1.9%; P = .030). Four (7.1%) of these 56 patients had acute postoperative exacerbation of pulmonary fibrosis and died because of this complication. No factors such as pulmonary function, serologic data, operative data, and histopathologic data were considered predictive risk factors for the acute exacerbation. The postoperative 5-year survival for pathologic stage I lung cancer was 61.6% for patients with idiopathic pulmonary fibrosis and 83.0% for patients without (P = .019). The causes of late death were the recurrence of cancer or respiratory failure owing to idiopathic pulmonary fibrosis. CONCLUSIONS Although idiopathic pulmonary fibrosis causes high mortality after pulmonary resection for lung cancer and poor long-term survival, long-term survival is possible in patients with these two fatal diseases. Therefore, in selected patients, idiopathic pulmonary fibrosis may not be a contraindication to pulmonary resection for stage I lung cancer.

[1]  M. Takahama,et al.  Operative indications for lung cancer with idiopathic pulmonary fibrosis. , 2007, The Thoracic and cardiovascular surgeon.

[2]  S. Katsaragakis,et al.  Postresectional pulmonary oxidative stress in lung cancer patients. The role of one-lung ventilation. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  I. Mikami,et al.  Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. , 2004, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[4]  K. Nakata,et al.  [Fatal acute exacerbation of idiopathic pulmonary fibrosis/usual interstitial pneumonia initially in the right lung after surgery lobectomy for left lung cancer]. , 2004, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

[5]  T. Okamoto,et al.  Clinical analysis of interstitial pneumonia after surgery for lung cancer. , 2004, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[6]  Y. Ohtani,et al.  Cyclosporin A followed by the treatment of acute exacerbation of idiopathic pulmonary fibrosis with corticosteroid. , 2003, Internal medicine.

[7]  A. Nicholson,et al.  Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. , 2003, The Journal of thoracic and cardiovascular surgery.

[8]  E. Martinod,et al.  Surgical resection of lung cancer in patients with underlying interstitial lung disease. , 2002, The Annals of thoracic surgery.

[9]  D. Schroeder,et al.  High short-term mortality following lung biopsy for usual interstitial pneumonia. , 2001, The European respiratory journal.

[10]  D. Schroeder,et al.  Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. , 2000, American journal of respiratory and critical care medicine.

[11]  J. Fujita,et al.  Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. , 1998, The European respiratory journal.

[12]  I. D. Johnston,et al.  Clinical Investigations: BAC, UIP, SODSurvival in Patients With Cryptogenic Fibrosing Alveolitis: A Population-Based Cohort Study , 1998 .

[13]  M. Yoshida,et al.  The effect of low-dose inhalation of nitric oxide in patients with pulmonary fibrosis. , 1997, The European respiratory journal.

[14]  S. Yokota,et al.  [Characteristics and management of patients with lung cancer and idiopathic interstitial pneumonia]. , 1996, Nihon Kyobu Shikkan Gakkai zasshi.

[15]  Y. Mizushima,et al.  Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. , 1995, Chest.

[16]  H. Kreisman,et al.  Fatal pulmonary toxicity following oral etoposide therapy. , 1995, Lung cancer.

[17]  G. Hunninghake,et al.  Approaches to the treatment of pulmonary fibrosis. , 1995, American journal of respiratory and critical care medicine.

[18]  H. Magnussen,et al.  The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. , 1994, The European respiratory journal.

[19]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[20]  D. Schwartz,et al.  Determinants of survival in idiopathic pulmonary fibrosis. , 1994, American journal of respiratory and critical care medicine.

[21]  K. Nakata,et al.  [Acute exacerbation in idiopathic interstitial pneumonia]. , 1984, Nihon Kyobu Shikkan Gakkai zasshi.

[22]  E. Anderson Hudson et al. , 1977 .

[23]  A. Liebow,et al.  Relationship of interstitial pneumonia honeycombing and atypical epithelial proliferation to cancer of the lung , 1965, Cancer.

[24]  T. Yano,et al.  [Prophylactic administration of steroid for interstitial pneumonia after pulmonary resection for lung cancer]. , 2005, Kyobu geka. The Japanese journal of thoracic surgery.

[25]  R. Hubbard,et al.  Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. , 2000, American journal of respiratory and critical care medicine.

[26]  K P Offord,et al.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.

[27]  E. Borden,et al.  Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non‐small cell lung cancer , 1986, Cancer.

[28]  D. Mapel,et al.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts , 2022 .